Very Late Relapse in Pediatric Acute Myeloid Leukemia: A Case Report and Brief Literature Review Article

Full Text via DOI: 10.1097/MPH.0000000000001989 Web of Science: 000680076400008

Cited authors

  • Unis GD, VanderVeen N, Fletcher M, Vasquez RJ


  • Acute myeloid leukemia (AML) is a heterogenous group of diseases affecting similar to 500 children in the United States annually. With current therapy, 90% of these children will obtain complete remission. However, 30% to 40% of these patients will relapse, most commonly within the first 3 years. Very late relapses, defined as relapse occurring >5 years after complete remission, are rare, accounting for 1% to 3% of relapses. We describe a patient with AML harboring an AFDN/KMT2A translocation who relapsed 12 years after matched sibling stem cell transplant, provide a brief review of the relevant literature, and describe proposed mechanisms to explain very late relapse AML.

Publication date

  • 2021

International Standard Serial Number (ISSN)

  • 1077-4114

Number of pages

  • 4

Start page

  • 236

End page

  • 239


  • 43


  • 6